Absolute Lymphocyte Count as a Prognostic Factor for Merkel Cell Carcinoma

2012 ◽  
Vol 84 (3) ◽  
pp. S136-S137
Author(s):  
M.E. Johnson ◽  
A. Turaka ◽  
F. Zhu ◽  
T. Galloway ◽  
J. Farma ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Lymphocyte Count ◽  
Absolute Lymphocyte Count ◽  
Merkel Cell

Absolute Lymphocyte Count: A Novel Prognostic Factor for Merkel Cell Carcinoma

2013 ◽  
Vol 3 (2) ◽  
pp. S10-S11
Author(s):  
M.E. Johnson ◽  
A. Turaka ◽  
F. Zhu ◽  
T. Galloway ◽  
J. Farma ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Lymphocyte Count ◽  
Absolute Lymphocyte Count ◽  
Merkel Cell

Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinoma

2014 ◽  
Vol 70 (6) ◽  
pp. 1028-1035 ◽  
Author(s):  
Matthew E. Johnson ◽  
Fang Zhu ◽  
Tianyu Li ◽  
Hong Wu ◽  
Thomas J. Galloway ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Lymphocyte Count ◽  
Absolute Lymphocyte Count ◽  
Merkel Cell ◽  
Potential Prognostic Factor

scholarly journals Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)

2021 ◽  
Vol 11 ◽  
Author(s):  
Marco Rastrelli ◽  
Paolo Del Fiore ◽  
Irene Russo ◽  
Jacopo Tartaglia ◽  
Alessandro Dal Monico ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Regional Lymph Node ◽  
Treatment Strategies ◽  
University Hospital ◽  
Merkel Cell ◽  
Pathological Characteristics ◽  
Negative Prognostic Factor

BackgroundMerkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. The incidence of the disease has undergone a significant increase in recent years, which is caused by an increase in the average age of the population and in the use of immunosuppressive therapies. MCC is an aggressive pathology, which metastasizes early to the lymph nodes. These characteristics impose an accurate diagnostic analysis of the regional lymph node district with radiography, clinical examination and sentinel node biopsy. In recent years, there has been a breakthrough in the treatment of the advanced pathology thanks to the introduction of monoclonal antibodies acting on the PD-1/PD-L1 axis. This study aimed to describe the clinico-pathological characteristics, treatment strategies and prognostic factors of MCC.MethodsA retrospective cohort study was conducted involving 143 consecutive patients who were diagnosed and/or treated for MCC. These patients were referred to the Veneto Institute of Oncology IOV-IRCCS and to the University Hospital of Padua (a third-level center) in the period between December 1991 and January 2020. In the majority of cases, diagnosis took place at the IOV. However, some patients were diagnosed elsewhere and subsequently referred to the IOV for a review of the diagnosis or to begin specific therapeutic regimens.Results143 patients, with an average age of 71 years, were affected mainly with autoimmune and neoplastic comorbidities. Our analysis has shown that age, autoimmune comorbidities and the use of therapy with immunomodulating drugs (which include corticosteroids, statins and beta-blockers) are associated with a negative prognosis. In this sense, male sex is also a negative prognostic factor.ConclusionsAutoimmune and neoplastic comorbidities were frequent in the studied population. The use of drugs with immunomodulatory effects was also found to be a common feature of the population under examination. The use of this type of medication is considered a negative prognostic factor. The relevance of a multidisciplinary approach to the patient with MCC is confirmed, with the aim of assessing the risks and benefits related to the use of immunomodulating therapy in the individual patient.

scholarly journals Intron 4–5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance

2021 ◽  
Author(s):  
Costantino Ricci ◽  
Luca Morandi ◽  
Francesca Ambrosi ◽  
Alberto Righi ◽  
Dino Gibertoni ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Skin Tumor ◽  
Epigenetic Mechanism ◽  
Merkel Cell ◽  
Pathological Features ◽  
Intron 4 ◽  
Overall Mortality

AbstractMerkel cell carcinoma (MCC) is an aggressive skin tumor with neuroendocrine differentiation, mainly affecting elderly population or immunocompromised individuals. As methylation of the human telomerase reverse transcriptase (mhTERT) has been shown to be a prognostic factor in different tumors, we investigated its role in MCC, in particular in intron 4–5 where rs10069690 has been mapped and recognized as a cancer susceptibility locus. DNA methylation analysis of hTERT gene was assessed retrospectively in a cohort of 69 MCC patients from the University of Bologna, University of Turin and University of Insubria. Overall mortality was evaluated with Kaplan-Meier curves and multivariable Royston-Parmar models. High levels of mhTERT (mhTERThigh) (HR = 2.500, p = 0.015) and p63 (HR = 2.659, p = 0.016) were the only two clinico-pathological features significantly associated with a higher overall mortality at the multivariate analysis. We did not find different levels of mhTERT between MCPyV (+) and (−) cases (21 vs 14, p = 0.554); furthermore, mhTERThigh was strongly associated with older age (80.5 vs 72 years, p = 0.026), no angioinvasion (40.7% vs 71.0%, p = 0.015), lower Ki67 (50 vs 70%, p = 0.005), and PD-L1 expressions in both tumor (0 vs 3%, p = 0.021) and immune cells (0 vs 10%, p = 0.002). mhTERT is a frequently involved epigenetic mechanism and a relevant prognostic factor in MCC. In addition, it belongs to the shared oncogenic pathways of MCC (MCPyV and UV-radiations) and it could be crucial, together with other epigenetic and genetic mechanisms as gene amplification, in determining the final levels of hTERT mRNA and telomerase activity in these patients.

Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor

2018 ◽  
Vol 32 (6) ◽  
pp. e236-e237 ◽  
Author(s):  
K.V. Orlova ◽  
V.V. Delektorskaya ◽  
Y.V. Vishnevskaya ◽  
T.T. Kondratieva ◽  
N.F. Orel ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Somatostatin Receptor ◽  
Receptor Type ◽  
Merkel Cell

scholarly journals Primary Tumor Thickness as a Prognostic Factor in Merkel Cell Carcinoma: The Next Big Thing?

2012 ◽  
Vol 19 (11) ◽  
pp. 3307-3309 ◽  
Author(s):  
Vernon K. Sondak ◽  
Jonathan S. Zager ◽  
Jane L. Messina
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Primary Tumor ◽  
Tumor Thickness ◽  
Merkel Cell

Merkel cell carcinoma with sarcomatous differentiation: is it a poor prognostic factor?

2012 ◽  
Vol 52 (1) ◽  
pp. 93-95 ◽  
Author(s):  
Elisabeth Gomez-Moyano ◽  
Ángel Vera-Casaño ◽  
Andrés Sanz-Trelles ◽  
Leandro Martinez
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Merkel Cell ◽  
Poor Prognostic Factor
Sign in / Sign up

Export Citation Format

Share Document